A Virus-based Vaccine May Prevent Cervical Cancer.
High-risk human papillomaviruses (HPVs) are now recognized as the etiologic agents of invasive cervical cancer, a major cancer in women. A single HPV type (type 16) is responsible for about 50% of the cancers. The major capsid protein of papillomaviruses, L1, when expressed by recombinant DNA technology, has the intrinsic ability to assemble into virus-like particles (VLPs). In a recent study, a vaccine based on HPV 16 VLPs was tested in a placebo-controlled proof-of-principle trial in young women in the United States. The vaccine was found to prevent 100% of incident persistent HPV 16 infections and HPV 16-associated cervical intraepithelial neoplasia. These results offer promise that cervical cancer will be preventable by an HPV-based vaccine. Studies planned or in progress are examining the efficacy of the vaccine in men, in HIV-infected individuals, and in other parts of the world. Attempts are being made to prepare vaccines that can be administered more easily to large populations.
Gravitt
Patti E
PE
Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Baltimore, MD 21205, USA. kvshah@jhsph.edu.
Shah
Keerti V
KV
J Virol. 1996 Feb;70(2):960-5
8551636
J Natl Cancer Inst. 2003 Aug 6;95(15):1128-37
12902442
Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1800-5
9465097
Virology. 1996 May 1;219(1):37-44
8623552
Lancet Infect Dis. 2002 Jul;2(7):395-403
12127351
J Infect Dis. 1999 Nov;180(5):1415-23
10515798
Infect Immun. 1997 Aug;65(8):3328-36
9234794
J Natl Cancer Inst Monogr. 2003;(31):111-6
12807954
J Virol. 2003 Sep;77(17 ):9211-20
12915537
Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12180-4
1334560
J Virol. 1995 Jun;69(6):3959-63
7745754
J Natl Cancer Inst. 2001 Feb 21;93(4):284-92
11181775
Cancer Epidemiol Biomarkers Prev. 1997 Jun;6(6):387-400
9184771
Lancet. 2004 Nov 13-19;364(9447):1757-65
15541448
Virology. 2000 May 10;270(2):254-7
10792983
Virology. 1997 Jul 21;234(1):93-111
9234950
J Pathol. 1999 Sep;189(1):12-9
10451482
J Natl Cancer Inst. 2004 Apr 21;96(8):604-15
15100338
N Engl J Med. 2003 Feb 6;348(6):518-27
12571259
J Natl Cancer Inst. 1995 Jun 7;87(11):796-802
7791229
N Engl J Med. 2002 Nov 21;347(21):1645-51
12444178
J Gen Virol. 1993 Apr;74 ( Pt 4):763-8
8385700
Int J Cancer. 2003 Oct 10;106(6):896-904
12918067
N Engl J Med. 1998 Feb 12;338(7):423-8
9459645
Immunol Cell Biol. 2002 Feb;80(1):21-9
11869359
J Infect Dis. 2002 Nov 15;186(10):1396-402
12404154
J Infect Dis. 2003 Jul 15;188(2):327-38
12854090
Vaccine. 1999 Apr 23;17(17):2129-35
10367945
Vaccine. 2000 Feb 18;18 Suppl 1:S35-8
10683542
JAMA. 2003 Aug 13;290(6):781-9
12915431
Vaccine. 2003 Oct 1;21(27-30):4256-60
14505907
Br J Cancer. 2003 Jan 13;88(1):63-73
12556961
J Virol. 2003 Aug;77(16):8702-11
12885889
Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11553-7
8524802
Lancet Infect Dis. 2003 Aug;3(8):469-75
12901889
J Virol. 1993 Jan;67(1):315-22
8380079
J Natl Cancer Inst. 2000 May 3;92(9):709-20
10793107